- The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days.
- The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection.
- This approval follows the recent FDA nod for Veklury for non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19.
- Related: Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients.
- Under the expanded indication, a three-day Veklury treatment regimen is recommended to help prevent hospitalization in high-risk non-hospitalized COVID-19 pediatric patients.
- For hospitalized pediatric patients who do not require invasive mechanical ventilation, a 5-day treatment course is recommended.
- The approval was supported by results from the CARAVAN Phase 2/3 study. Of the 53 pediatric patients, no new safety signals were apparent for patients treated with Veklury.
- Overall, 75% and 85% showed clinical improvement at Day 10 and the last assessment, respectively, while 60% and 83% were discharged by Day 10 and Day 30.
- Price Action: GILD shares closed at $62.65 on Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks